| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Journal of Lipid Research, Vol 37, 508-517, Copyright © 1996 by Lipid Research, Inc.
G Luc, C Fievet, D Arveiler, AE Evans, JM Bard, F Cambien, JC Fruchart and P Ducimetiere
Apolipoprotein (apo) C-III and apoE are components of two major classes of
plasma lipoproteins, i.e., apoB- and non-apoB-containing lipoproteins. To
analyze the relationship between the distribution of apoC-III and apoE
among lipoproteins and coronary heart disease, we compared the distribution
of these two apolipoproteins in survivors of myocardial infarction (MI) and
control subjects, within and between populations at contrasting risk for
MI. ApoC-III and apoE concentrations were determined in plasma devoid of
apoB-containing lipoproteins by immunoprecipitation using a specific
anti-apoB antiserum. These assays referred to apoC-III-Lp non-B and apoE-Lp
non- B, respectively. By examining the difference with total plasma
apoC-III and apoE levels, we calculated apoC-III and apoE in
apoB-containing lipoproteins (apoCIII-LpB and apoE-LpB, respectively).
These determinations were performed in control subjects and in survivors of
MI, all males aged 25 to 64 years. They were recruited in Northern Ireland
and France, countries characterized by a large difference in the incidence
of coronary heart disease. In univariate analysis, apoCIII-LpB appeared
significantly higher and the apoC-III ratio (apoC- III-Lp
non-B/apoC-III-LpB) significantly lower in MI survivors than in control
subjects in both countries. ApoE-LpB was higher in MI survivors than in
control subjects in Northern Ireland but not in France. The two French and
Irish control populations differed for apoC-ILL-Lp non-B, apoC-III ratio,
and apoE ratio, which were higher in France than in Northern Ireland, and
for apoC-III-LpB, apoE, and apoE-LpB, which were lower. Multivariate
analysis showed that no parameter involving apoC- III and apoE was more
discriminatory than HDL-cholesterol, cholesterol, and triglycerides or
apoA-I, apoB, and triglycerides between controls and MI subjects. In
contrast, the apoC-III ratio was a better discriminatory parameter between
the two control populations than the listed parameters. The differences
between the two control populations are of particular interest because they
are not biased by the presence of disease or the large difference of the
incidence in coronary heart disease between the two countries. It is
suggested that the distribution of apoC-III among lipoproteins may play a
role in the different susceptibility of the two populations to the
atherogenic process.
ARTICLES
Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde
Department of Atherosclerosis, Institut Pasteur de Lille, France.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C.-Q. Lai, D. Corella, S. Demissie, L. A. Cupples, X. Adiconis, Y. Zhu, L. D. Parnell, K. L. Tucker, and J. M. Ordovas Dietary Intake of n-6 Fatty Acids Modulates Effect of Apolipoprotein A5 Gene on Plasma Fasting Triglycerides, Remnant Lipoprotein Concentrations, and Lipoprotein Particle Size: The Framingham Heart Study Circulation, May 2, 2006; 113(17): 2062 - 2070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Olivieri, N. Martinelli, M. Sandri, A. Bassi, P. Guarini, E. Trabetti, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, et al. Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant" T-455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction Clin. Chem., February 1, 2005; 51(2): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Cohn, C. Rodriguez, H. Jacques, M. Tremblay, and J. Davignon Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE J. Lipid Res., August 1, 2004; 45(8): 1572 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Carmena, P. Duriez, and J.-C. Fruchart Atherogenic Lipoprotein Particles in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-2 - III-7. [Abstract] [Full Text]
|
|
|
|
|
|
J.-C. Fruchart, M. C. Nierman, E. S. G. Stroes, J. J. P. Kastelein, and P. Duriez New Risk Factors for Atherosclerosis and Patient Risk Assessment Circulation, June 15, 2004; 109(23_suppl_1): III-15 - III-19. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. M. Dallinga-Thie, I. I.L. Berk-Planken, A. H. Bootsma, and H. Jansen Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B-Containing Lipoprotein and HDL in Type 2 Diabetes: A potential mechanism to lower plasma triglycerides Diabetes Care, June 1, 2004; 27(6): 1358 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Chiuve, L. A. Martin, H. Campos, and F. M. Sacks Effect of the Combination of Methyltestosterone and Esterified Estrogens Compared with Esterified Estrogens Alone on Apolipoprotein CIII and Other Apolipoproteins in Very Low Density, Low Density, and High Density Lipoproteins in Surgically Postmenopausal Women J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2207 - 2213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Olivieri, A. Bassi, C. Stranieri, E. Trabetti, N. Martinelli, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, and R. Corrocher Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease J. Lipid Res., December 1, 2003; 44(12): 2374 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Cohn, R. Batal, M. Tremblay, H. Jacques, L. Veilleux, C. Rodriguez, O. Mamer, and J. Davignon Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism J. Lipid Res., October 1, 2003; 44(10): 1976 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Blackett, R. Germany, B. Sambo, and P. Alaupovic Apolipoprotein C-III Bound to Apolipoprotein B-containing Lipoproteins in Obese Girls Clin. Chem., February 1, 2003; 49(2): 303 - 306. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Berneis and R. M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Olivieri, C. Stranieri, A. Bassi, B. Zaia, D. Girelli, F. Pizzolo, E. Trabetti, S. Cheng, M. A. Grow, P. F. Pignatti, et al. ApoC-III gene polymorphisms and risk of coronary artery disease J. Lipid Res., September 1, 2002; 43(9): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Montoya, A. Porres, S. Serrano, J. C. Fruchart, P. Mata, J. A. G. Gerique, and G. R. Castro Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity Am. J. Clinical Nutrition, March 1, 2002; 75(3): 484 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Schiele, M. Vincent-Viry, M. Starck, B. Beaud, G. Hennache, G. Siest, S. Visvikis, and B. Herbeth Apolipoprotein E in Apolipoprotein B (apo B)- and Non-apo B-containing Lipoproteins in 3523 Participants in the Stanislas Cohort: Biological Variation and Genotype-specific Reference Limits Clin. Chem., February 1, 2002; 48(2): 291 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Campos, D. Perlov, C. Khoo, and F. M. Sacks Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia J. Lipid Res., August 1, 2001; 42(8): 1239 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bard, M. A. Charles, I. Juhan-Vague, P. Vague, P. Andre, M. Safar, J. C. Fruchart, E. Eschwege, and o. b. o. t. BIGPRO Study Group Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity : The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bonnet, J.-B. Ruidavets, J. Tuech, J. FerriÈres, X. Collet, J. Fauvel, P. Massip, and B. Perret Apoprotein C-III and E-Containing Lipoparticles Are Markedly Increased in HIV-Infected Patients Treated with Protease Inhibitors: Association with the Development of Lipodystrophy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 296 - 302. [Abstract] [Full Text]
|
|
|
|
|
|
A. Tailleux, M. Bouly, G. Luc, G. Castro, J.-M. Caillaud, N. Hennuyer, P. Poulain, J.-C. Fruchart, N. Duverger, and C. Fievet Decreased Susceptibility to Diet-Induced Atherosclerosis in Human Apolipoprotein A-II Transgenic Mice Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2453 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Sacks, P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, M. A. Pfeffer, and E. Braunwald VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial Circulation, October 17, 2000; 102(16): 1886 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Cohn, C. Marcoux, and J. Davignon Detection, Quantification, and Characterization of Potentially Atherogenic Triglyceride-Rich Remnant Lipoproteins Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2474 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Khoo, H. Campos, H. Judge, and F. M. Sacks Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content J. Lipid Res., February 1, 1999; 40(2): 202 - 212. [Abstract] [Full Text]
|
|
|
|
|
|
H. Jansen, G. Chu, C. Ehnholm, J. Dallongeville, V. Nicaud, and P. J. Talmud The T Allele of the Hepatic Lipase Promoter Variant C-480T Is Associated With Increased Fasting Lipids and HDL and Increased Preprandial and Postprandial LpCIII:B : European Atherosclerosis Research Study (EARS) II Arterioscler. Thromb. Vasc. Biol., February 1, 1999; 19(2): 303 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism Circulation, November 10, 1998; 98(19): 2088 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dallongeville, J.-C. Fruchart, P. Maigret, S. Bertolini, G. Bittolo Bon, M. M. Campbell, M. Farnier, J. Langan, G. Mahla, P. Pauciullo, et al. Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 103 - 110. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
